Financial Performance & Pipeline Funding - MannKind reported total revenue of $78 million for Q1 2025, an 18% increase compared to $66 million in Q1 2024[86] - Tyvaso DPI collaboration generated $30 million in royalty revenue in Q1 2025, a 32% increase compared to Q1 2024[11, 86] - Manufacturing-related revenue from Tyvaso DPI was $29 million in Q1 2025, a 16% year-over-year increase[11, 50] - The company's cash, cash equivalents, and investments stand at $198 million[13] - Tyvaso DPI revenue for the last four quarters reached $1.1 billion[50] Afrezza Development & Market Expansion - Afrezza demonstrated a 20% growth in new prescriptions (NRx) in Q1 2025 compared to Q1 2024[11] - The company anticipates a label update for Afrezza in Q4 2025[11] - MannKind expects to submit a supplemental Biologics License Application (sBLA) for pediatric indication expansion in mid-2025[11] - Projected sales of Afrezza are estimated to be over $200 million, with every 10% of pediatric market share potentially adding ~$150 million in annual revenue[41] MNKD-101 & MNKD-201 Clinical Trials - MannKind expects to meet the interim enrollment target for the Clofazimine Inhalation Suspension (MNKD-101) Phase 3 global enrollment by the end of 2025, with approximately 70 patients randomized to date[11] - The company plans to advance Nintedanib DPI (MNKD-201) into the next phase of global development in the second half of 2025[11]
MannKind (MNKD) 2025 Earnings Call Presentation